ANDREW J. SCHWAB   Managing Partner, 5AM Ventures

Prior to founding 5AM in 2002, Andrew was a Principal at Bay City Capital. After joining Bay City Capital in 1999, he led the firm’s investment and merchant banking activities for such companies as Cubist, Metabolex, PTC Therapeutics, Symyx and Syrrx. Previously Andrew was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of Directors of Biodesy, Cleave, DVS (acquired by Fluidigm), Flexion (IPO), Ikaria, Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix), RuiYi, Synosia (acquired by Biotie) and Viveve. Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of Davidson’s 1992 Final Four soccer team.

BILL BURKOTH   Executive Director, Pfizer Ventures

Since joining Pfizer Ventures, the venture capital arm of Pfizer Inc., in early 2004, Bill has played an instrumental role in numerous new venture capital investments, including Avid Radiopharmaceuticals (acquired by Eli Lilly), Clovis Oncology (Nasdaq: CLVS), DVS Sciences (acquired by Fluidigm), Evolution Benefits (acquired by Genstar Capital), and HandyLab (acquired by Becton Dickinson). Bill currently also serves on the board of directors of NeuMoDx Molecular, Novocure, and RefleXion Medical and as a board observer of Epic Sciences, HD Biosciences (Shanghai, China), M2S, and Nodality. Prior to joining Pfizer, Bill worked in Business Development at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals. Prior to his roles in business development, Bill was an analyst at Bay City Capital. Bill received a BA in chemistry from Whitman College and an MBA from Columbia Business School.


Joe Victor brings more than 30 years of experience fostering product innovation and building value for customers, shareholders, and employees. Most recently, he was CEO of privately held DVS Sciences, a designer and manufacturer of a transformational bioanalytical platform including high-end mass cytometry instruments and associated consumables. DVS was sold in early 2014 to Fluidigm, Inc., a leading Life Sciences publicly held company.  Prior to DVS, Mr. Victor was CEO of Applied Precision Inc., a manufacturer of high performance microscopy systems for life sciences research and drug development acquired by GE Healthcare in 2011. Before that he drove significant sales growth, new product development and overall profitability of the Applied Precision business in the roles of President, Sr. VP Life Sciences, VP R&D / Operations, and VP R&D. Prior to Applied Precision, Mr. Victor held various executive management and technical positions in the high technology, aviation, and energy markets.  Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington. Mr. Victor is based in the Seattle area and currently serves on the following company board of directors:  Biodesy, Glencoe Software, Precision Nanosystems, Purigen, and RareCyte.  Mr Victor also serves as an advisory board member to the Harvard Program in Therapeutic Science and the UC Davis Ecosystem for Biophotonics Innovation.


Josh is the Founder of Biodesy and the inventor of the Second Harmonic Generation (SHG) technique for studying biological molecules. Josh was awarded a number of NSF and NIH grants and obtained key scientific breakthroughs that galvanized the scientific and venture capital communities.  Previously, Josh was a postdoctoral fellow in the Dept. of Chemistry at Columbia University and the Dept. of Physics at Utrecht University in the Netherlands, as well as a guest researcher at the Cavendish Laboratory at the University of Cambridge, UK. His expertise and interests are in the areas of Biophysics and Physical Chemistry. At Biodesy he leads a team focused on creating novel techniques with SHG and applying them to problems in drug discovery and structural biology.  Josh received his PhD from Stanford University where he studied the reaction center protein, the marvelous engine at the heart of photosynthesis which converts light into chemical energy.


Andrej Sali  

Andrej Sali received his BSc degree in chemistry from the University of Ljubljana, Slovenia, in 1987; and his PhD from Birkbeck College, University of London, UK, in 1991, under the supervision of Professor Tom L. Blundell, where he developed the MODELLER program for comparative modeling of protein structures. He was then a postdoc with Professor Martin Karplus at Harvard University as a Jane Coffin Childs Memorial Fund fellow, studying lattice Monte Carlo models of protein folding. From 1995 to 2002, he was first an Assistant Professor and then an Associate Professor at The Rockefeller University. In 2003, he moved to University of California, San Francisco, as a Professor of Computational Biology in the Department of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, and California Institute for Quantitative Biosciences (QB3). He was a Sinsheimer Scholar (1996), an Alfred P. Sloan Research Fellow (1998), an Irma T. Hirschl Trust Career Scientist (2000), the recipient of the Zois Award of Science Ambassador of Republic of Slovenia (2007), and elected a Fellow of International Society for Computational Biology (2014). He has been an Editor of Structure since 2002. He is also a Founder of Prospect Genomix that merged with Structural Genomix (2001); and of Global Blood Therapeutics (2012). Dr. Sali develops and applies computational methods for determining and modulating structures and functions of proteins and their assemblies.

Richard Ulevitch  

Richard J. Ulevitch, Ph.D. joined 5AM Ventures in February 2008 as a Venture Partner. Previously he was Chairman of 5AM’s Scientific Advisory Board while serving as Professor and Chairman of the Department of Immunology at The Scripps Research Institute in La Jolla, California. He remains as Professor and Chairman Emeritus at The Scripps Research Institute. For nearly three decades, Dr. Ulevitch has performed research to understand the role of the immune system in human disease. He serves as a scientific advisor to Aravis Ventures, a European life science venture capital fund and previously served as an advisor to the Lombard Odier Immunology Fund, where he evaluated numerous biotechnology companies over a fifteen-year span. Dr. Ulevitch serves or has served on the Scientific Advisory Boards of Arvinas, Biodesy, Bird Rock Bio, Cidara (NASDAQ: CDTX), Cleave, Envoy (acquired by Takeda), Ideaya, Igenica, Ikaria (acquired by Mallinckrodt), Pulmatrix (NASDAQ: PULM) as well as on the Board of PhaseRx. Dr. Ulevitch received an A.B. from Washington and Jefferson College and a Ph.D. in Biochemistry from the University of Pennsylvania. Dr. Ulevitch is based in the Menlo Park, CA office.

Erica Ollmann Saphire  

Erica Ollmann Saphire, Ph.D. is a Professor of Immunology and Microbial Science at The Scripps Research Institute. Her research combines structural biology with cellular virology and immunology to understand and defeat viral pathogens. Her team has revealed the structures of the trimeric, prefusion glycoproteins for the Ebola, Lassa, Sudan and Marburg viruses, revealed neutralizing and non-neutralizing antibody epitopes, how these viruses drive themselves into cells, how they suppress immune function, and where the viruses are vulnerable. Her team solved the only structure of the entire human antibody itself and made the groundbreaking discovery that expanded a central dogma of molecular biology: certain proteins of these viruses rearrange their 3D structures to achieve different functions at different stages of their life cycle. She is the founder and Director of the Viral Hemorrhagic Fever Immunotherapeutic Consortium, a 43+ laboratory, 5-continent basic and translational research effort.  This organization, the VIC, united the field into a single force to understand and provide antibody therapeutics against Ebola, Marburg, Lassa and other viruses. Her work has been recognized at the White House with a Presidential Early Career Award, by the Burroughs Wellcome Fund, by young investigator awards from ASBMB, ASM and the International Society for Antiviral Research, and by the Surhain Sidhu award for the most outstanding contribution to the field of diffraction. She is a Fellow of AAM and AAAS, and serves on the Scientific Leadership Boards of the Global Virus Network and the Viral Hemorrhagic Fever Immunotherapeutic Consortium.

Frank McCormick  

Frank McCormick, PhD, FRS, is a Professor at the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated and led drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. Sorafenib is being tested in multiple indications worldwide. In addition, Dr. McCormick’s group led to the identification of the CDK4 kinase inhibitor, Palbociclib, approved for treating advanced breast cancer. Dr. McCormick’s current research interests center on the fundamental differences between normal and cancer cells that can allow the discovery of novel therapeutic strategies.

Dr. McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. Dr.  McCormick is the author of over 320 scientific publications and holds more than 20 issued patents. He was Director of the Helen Diller Family Comprehensive Cancer Center from 1997 to 2014. He also served as President, 2012-2013, for the American Association for Cancer Research (AACR). Since 2013 he has taken a leadership role at the Frederick National Lab for Cancer Research, overseeing an NCI supported national effort to develop therapies against Ras-driven cancers. These cancers include most pancreatic cancers, and many colorectal and lung cancers, and are amongst the most difficult cancers to treat.

Theodore Jardetzky  

Theodore (Ted) Jardetzky is a Professor in the Department of Structural Biology in the Stanford School of Medicine where he is affiliated with the Programs in Biophysics and Immunology and a fellow of the Stanford Chem-H Institute. Professor Jardetzky’s research focuses on understanding mechanisms of virus entry and neutralization, as well as the allergic response mediated by IgE antibodies. Professor Jardetzky has made seminal contributions to understanding how the recognition of host receptors by viral glycoproteins initiates cell-specific entry of herpesviruses and paramyxoviruses, providing mechanistic insight into antibody-mediated neutralization and targets for subunit vaccine development.  His research has clarified how IgE antibodies interact with high affinity cellular receptors that trigger inflammatory responses associated with food allergies and asthma. His laboratory has discovered novel ‘disruptive’ inhibitors targeting this IgE receptor interaction that rapidly dissociate IgE complexes, demonstrating the potential for the discovery of a novel and more potent class of anti-allergy therapeutics. Professor Jardetzky’s research is funded by the National Institutes of Health and the Department of Defense and has been recognized by the awarding of an NIH MERIT award and his selection as a Pew Scholar in the Biomedical Sciences, a Scholar of the Leukemia and Lymphoma Society, an Investigator of the Cancer Research Institute, a Fellow of the American Academy for Microbiology and a Fellow of the American Association for the Advancement of Science.